ABSTRACT
This chapter aims to review the pharmacokinetic data regarding intraperitoneal (IP) chemotherapy following cytoreductive surgery (CRS) n peritoneal surface malignancy patients. Oxaliplatin is a third-generation platinum complex with proven cytotoxicity in colon and appendiceal neoplasms. Gemcitabine is a pyrimidine analogue with a wide range of in vitro cytotoxic activity, particularly against pancreatic cancer. Pemetrexed is multitargeted antifolate that belongs to the antimetabolites. It is an analogue of folic acid with cytotoxic activity against a variety of malignancies, especially mesothelioma, ovarian cancer and colon cancer. The most advantageous exposure time for cytotoxic effects in peritoneal carcinomatosis (PC) patients should be carefully weighed against systemic exposure and bone marrow toxicity and degradation processes. Carboplatin is a higher molecular weight platinum compound than cisplatin mainly explored for IP use in PC from ovarian origin. The concept of IP chemotherapy in PC patients after optimal CRS has been proven in phase II–III trials.
